| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | iNV |
| Uniprot No | Q9Y283 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1065aa |
| 氨基酸序列 | MNKSENLLFAGSSLASQVHAAAVNGDKGALQRLIVGNSALKDKEDQFGRTPLMYCVLADRLDCADALLKAGADVNKTDHSQRTALHLAAQKGNYRFMKLLLTRRANWMQKDLEEMTPLHLTTRHRSPKCLALLLKFMAPGEVDTQDKNKQTALHWSAYYNNPEHVKLLIKHDSNIGIPDVEGKIPLHWAANHKDPSAVHTVRCILDAAPTESLLNWQDYEGRTPLHFAVADGNVTVVDVLTSYESCNITSYDNLFRTPLHWAALLGHAQIVHLLLERNKSGTIPSDSQGATPLHYAAQSNFAETVKVFLKHPSVKDDSDLEGRTSFMWAAGKGSDDVLRTMLSLKSDIDINMADKYGGTALHAAALSGHVSTVKLLLENNAQVDATDVMKHTPLFRACEMGHKDVIQTLIKGGARVDLVDQDGHSLLHWAALGGNADVCQILIENKINPNVQDYAGRTPLQCAAYGGYINCMAVLMENNADPNIQDKEGRTALHWSCNNGYLDAIKLLLDFAAFPNQMENNEERYTPLDYALLGERHEVIQFMLEHGALSIAAIQDIAAFKIQAVYKGYKVRKAFRDRKNLLMKHEQLRKDAAAKKREEENKRKEAEQQKGRRSPDSCRPQALPCLPSTQDVPSRQSRAPSKQPPAGNVAQGPEPRDSRGSPGGSLGGALQKEQHVSSDLQGTNSRRPNETAREHSKGQSACVHFRPNEGSDGSRHPGVPSVEKSRGETAGDERCAKGKGFVKQPSCIRVAGPDEKGEDSRRAAASLPPHDSHWKPSRRHDTEPKAKCAPQKRRTQELRGGRCSPAGSSRPGSARGEAVHAGQNPPHHRTPRNKVTQAKLTGGLYSHLPQSTEELRSGARRLETSTLSEDFQVSKETDPAPGPLSGQSVNIDLLPVELRLQIIQRERRRKELFRKKNKAAAVIQRAWRSYQLRKHLSHLRHMKQLGAGDVDRWRQESTALLLQVWRKELELKFPQTTAVSKAPKSPSKGTSGTKSTKHSVLKQIYGCSHEGKIHHPTRSVKASSVLRLNSVSNLQCIHLLENSGRSKNFSYNLQSATQPKNKTKP |
| 预测分子量 | 117,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于诺如病毒(Norovirus, NoV)重组蛋白的3篇代表性文献(注：iNV可能为特定缩写，此处假设为诺如病毒相关研究)：
---
1. **文献名称**：*"Expression and characterization of norovirus virus-like particles in a baculovirus system"*
**作者**：Jiang X, et al.
**摘要**：研究利用杆状病毒-昆虫细胞系统表达诺如病毒衣壳蛋白(VP1)，成功组装病毒样颗粒(VLPs)，并验证其结构与天然病毒相似，为疫苗开发提供基础。
---
2. **文献名称**：*"Escherichia coli-derived virus-like particles in vaccine development: A case study with norovirus"*
**作者**：Tan M, et al.
**摘要**：报道在大肠杆菌中高效表达诺如病毒重组衣壳蛋白，通过体外自组装形成VLPs，动物实验显示其诱导强效免疫应答，证明原核系统的可行性。
---
3. **文献名称**：*"Norovirus VLP vaccines: Clinical development and challenges"*
**作者**：Ball JM, et al.
**摘要**：综述诺如病毒VLPs作为候选疫苗的临床试验进展，分析重组蛋白表达优化、免疫保护效力及人群应用中的挑战。
---
**备注**：若iNV指代其他领域重组蛋白(如肿瘤或代谢相关)，建议提供更具体的关键词以便精准检索。以上文献聚焦诺如病毒重组蛋白的疫苗开发方向。
**Background of iNV Recombinant Protein**
The iNV (integrated neurovascular) recombinant protein is an engineered biomolecule designed to mimic or enhance critical signaling pathways at the neurovascular interface, a dynamic region where neural, vascular, and glial cells interact. This protein is typically constructed by fusing functional domains from naturally occurring proteins involved in angiogenesis, neuroprotection, and cell adhesion, such as vascular endothelial growth factor (VEGF), neural growth factor (NGF), and laminin. Its design aims to address complex disorders like stroke, traumatic brain injury, or neurodegenerative diseases, where simultaneous vascular repair and neural regeneration are essential for recovery.
Recombinant protein technology enables precise control over iNV's structure and function. By using expression systems like *E. coli*, yeast, or mammalian cells, researchers produce iNV with high purity and bioactivity. Post-translational modifications (e.g., glycosylation) in mammalian systems often enhance its stability and receptor-binding efficiency. The protein’s multifunctional nature allows it to promote endothelial cell proliferation (supporting blood vessel growth) while stimulating neurite outgrowth and synaptic plasticity, creating a synergistic microenvironment for tissue repair.
Preclinical studies highlight iNV’s potential in crossing the blood-brain barrier (BBB) when conjugated with targeting peptides, enabling non-invasive delivery. It also shows promise in biomaterial scaffolds for neural implants, aiding in functional recovery. Challenges include optimizing dosage, minimizing immune responses, and ensuring long-term efficacy. Nonetheless, iNV exemplifies the shift toward multi-target therapies in regenerative medicine, bridging gaps between neurobiology and vascular biology to tackle previously untreatable conditions.
×
